Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | PGK1 | P00558 | 1/20 | 0.36 |
| ▸ | PGK2 | P07205 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | TPMT | P51580 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL502038 | 0.97 | ALDH1A1 (0.40) | ALDH1A1TSHRPGK1PGK2TRPA1 | |
| SCHEMBL2261460 | 0.91 | PGK1 (0.42) | ALDH1A1TSHRPGK1PGK2TRPA1 | |
| SCHEMBL305652 | 0.81 | TACR1 (0.41) | ALDH1A1TSHRPGK1PGK2TRPA1 | |
| SCHEMBL30349373 | 0.81 | TACR1 (0.41) | ALDH1A1TSHRPGK1PGK2TRPA1 | |
| SCHEMBL11345442 | 0.79 | ALDH1A1 (0.55) | ALDH1A1PGK1PGK2IDH1ACHE | |
| SCHEMBL334160 | 0.79 | NR1D1 (0.35) | TSHRPGK1PGK2 | |
| SCHEMBL642656 | 0.79 | TACR1 (0.31) | PGK1PGK2TACR1 | |
| SCHEMBL2924850 | 0.79 | ACHE (0.36) | PGK1PGK2IDH1ACHE | |
| SCHEMBL13498488 | 0.76 | PARP10 (0.46) | MAOA | |
| SCHEMBL9616495 | 0.76 | IDO1 (0.38) | ALDH1A1TSHRTRPA1TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112789108-B | Catalyst for asymmetric hydrogenation of compounds containing carbon double bonds | 格拉斯如睦株式会社 | 2023-09-19 | — | — | CN | disclosed |
| US-20090149445-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | COGHLAN MICHAEL JOSEPH | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149445-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | NR5A1, NR3C2, NR3C1 | ALDH1A1 1812/4885TSHR 75/4885PGK1 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.